GlassScriptPhysician profile
Sze Ching Lee
NPI 1427252303
$5,968.85
in general payments reported to CMS, 2019-2025
20 companies · $75.94 in 2025
The $75.94 reported for 2025 was less than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $254 · 2020: $201 · 2021: $572 · 2022: $400 · 2023: $455 · 2024: $4,011 · 2025: $75.94.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Education: $3,635 · Food and Beverage: $907.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Education | $3,635.05 |
| Food and Beverage | $906.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Telix Pharmaceuticals | $3,500.00 | 2024 | Illuccix |
| Astellas Pharma US INC | $740.94 | 2019-2024 | Xtandi, Veozah |
| Pfizer INC. | $614.96 | 2019-2024 | |
| Sumitomo Pharma America, INC. | $207.66 | 2023-2025 | Gemtesa |
| Myovant Sciences INC. | $176.72 | 2021-2022 | |
| Abbvie INC. | $135.11 | 2021-2023 | |
| Progenics Pharmaceuticals, INC. | $110.96 | 2022-2024 | Pylarify |
| Astrazeneca Pharmaceuticals LP | $88.43 | 2023-2025 | Lynparza, Imfinzi |
| Janssen Biotech, INC. | $77.52 | 2019-2023 | Erleada |
| Coloplast Corp | $47.24 | 2020-2022 | |
| Urovant Sciences INC | $41.56 | 2022 | |
| C. R. Bard, INC. & Subsidiaries | $39.47 | 2023 | Bard Urinary Drainage Bag |
| Urogen Pharma, INC. | $33.40 | 2021 | |
| Merck Sharp & Dohme LLC | $25.81 | 2024 | Lynparza |
| Zyla Life Sciences, INC. | $23.57 | 2019 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $22.90 | 2021 | |
| Tolmar Pharmaceuticals, INC. | $22.56 | 2019 | |
| Allergan, INC. | $21.56 | 2019 | |
| Myriad Genetic Laboratories, INC. | $19.91 | 2022 | |
| Tolmar, INC. | $18.57 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sze Ching Lee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.